Research ArticleTracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors
Introduction
New approaches to breast cancer immunotherapies are based on natural killer (NK) cells [1], [2]. The NK-cell-based therapies provide a high and selective cytotoxicity against tumor cells without toxicity against nonmalignant cells. The antitumoral activity of NK cells has been extensively investigated [3], [4], [5]. Breast cancer immunotherapy with NK cells can be achieved by adoptive transfer of ex vivo expanded and activated autologous or donor-derived NK cells, or by activation of endogenous NK cells through systemic application of cytokines [6], [7]. The former approach includes the use of cytotoxic NK cell lines that are suitable for clinical use [8].
Based on the high intrinsic cytotoxic activity of the human NK cell line NK-92 against a wide range of malignancies and on lack of toxicity and tumorigenic potential, Phase I/II clinical trials have been initiated [3], [8], [9], [10]. However, NK-92 cells did not show specific cytotoxicity to HER2/neu-positive tumors. Thus, the parental NK-92 cell line has been genetically modified by retroviral transduction with an pL-scFv(FRP5)-zeta-SN vector. The resulting NK-92-scFv(FRP5)-zeta cell line expresses a chimeric antigen receptor that enhances the antitumoral activity of NK-92 cells, specifically to HER2/neu-expressing cells [11]. HER2/neu (ErbB2) is an antigen that is overexpressed in many human tumors of epithelial origin and is associated with increased disease recurrence and worse prognosis [12], [13].
The effectiveness of NK cell therapy in patients is evaluated by indirect measures such as reduced tumor markers and improved survival of patients [8]. Polymerase chain reaction (PCR)-based monitoring of NK-92 kinetics in the peripheral blood of patients revealed that apparently a large portion of NK-92-cells leave the circulation within minutes of transfusion. However, as the adoptively transfused NK-92 cells were not labeled, homing of NK-92 cells to the tumor site could not be confirmed in clinical studies. Consequently, one could argue that an apparent tumor response may have occurred due to other cytotoxic drugs that were given in conjunction with the NK cells.
New molecular imaging techniques that provide NK cell tracking could directly confirm or disprove the accumulation of the NK cells in tumor tissues [14], [15], [16], [17], [18], [19], [20], [21], [22]; thus, these techniques might be able to early identify responders and nonresponders after NK cell treatment. In addition, a direct NK-cell-tracking technique could help to further evaluate the activating and inhibitory mechanisms of the function and cytotoxicity of NK cells. Various imaging techniques, such as single photon emission computed tomography, positron emission tomography (PET), optical imaging (OI) and MRI, are available for cell tracking. OI is a new inexpensive, fast and noninvasive imaging technique, based on the detection of fluorescence, with a high sensitivity. However, this technique has limited anatomical resolution and is currently not available for clinical applications [19], [20]. MRI provides three-dimensional data with high anatomical resolution and high soft tissue contrast, but with limited sensitivity for the detection of small cell populations [14], [18], [21], [22], [23], [24], [25], [26], [27]. Labeling techniques with radioactive tracers provide a very high sensitivity [15], [16], [17], [28]. [18F]Fluoro-deoxy-glucose (FDG) PET has a distinctive advantage over other conventional nuclear medicine techniques — it provides superior spatial resolution in conjunction with a Food and Drug Administration (FDA)-approved PET radiopharmaceutical; thus, the technique would be readily applicable in patients.
In this study, [18F]FDG was chosen as a clinically applicable and widely available cell-labeling tracer with documented high specificity and sensitivity for cell detection [16], [29], [30], [31], [32], [33]. In addition, after phosphorylation to [18F]FDG-6-phosphate, it is trapped in cells without further metabolism. Since the rate of dephosphorylation is low, confounding signals from free [18F]FDG are minimal within the observed time period of 2 h postinjection (pi). Cell labeling with [18F]FDG for subsequent cell tracking with PET has been previously performed in our laboratory and in other laboratories [16], [29], [30], [31], [32], [33]. Most previous cell-labeling studies have been conducted using monocytes, white blood cells and bone marrow stem cells. Forstrom et al. [29] indicated the feasibility of leukocyte labeling with [18F]FDG and its high diagnostic potential in the PET imaging of inflammation and infection. Rini et al. [32] compared the labeling of leukocytes with [18F]FDG versus the labeling of leukocytes with 111In oxine and found comparable sensitivities and specificities of [18F]FDG–PET and 111In scintigraphy for the detection and characterization of inflammation. Few studies have applied [18F]FDG-labeling techniques to the labeling and in vivo tracking of cytotoxic T lymphocytes and NK cells. Melder et al. [28] and Ritchie at al. [33] described different approaches to the stable incorporation of the positron-emitting substance [18F]FDG into lymphocytes. However, they described some problems, such as limited tracer uptake into the cells and loss of [18F]FDG from labeled cells.
Thus, the purpose of this study was to optimize the labeling of genetically engineered NK-92-scFv(FRP5)-zeta (targeted against HER2/neu receptors) and parental NK-92 cells (not targeted against HER2/neu receptors) with [18F]FDG for subsequent in vivo tracking to HER2/neu-positive tumors.
Section snippets
Cells and culture conditions
Pilot studies were performed with mononuclear cells from umbilical cord blood (UCB), which was collected from the umbilical cord vein after normal full-term delivery. UCB was collected in heparin-flushed syringes, stored at 4°C and processed within 24 h of collection. Low-density cells were isolated using Biocoll density centrifugation (d=1.077 g/ml; Biochrom, Berlin, Germany). After centrifugation at 1000×g for 20 minutes, mononuclear interphase cells were collected and washed once in HF/2+
In vitro studies
Pilot studies on mononuclear cells showed a steadily increasing [18F]FDG uptake for up to 60 min pi, followed by a plateau (Fig. 1, Fig. 2). Consequently, further incubation of cells with [18F]FDG did not result in further cellular uptake. Mean labeling efficiencies (percentage of [18F]FDG uptake) of FDG-labeled mononuclear cells were 47% after 30 min, 50% after 60 min and 45% after 120 min of incubation at each level of radioactivity (0.37, 3.7 and 37 MBq, respectively). There was no
Discussion
In this study, we could prove that parental NK-92 and genetically engineered NK-92-scFv(FRP5)-zeta cells can be effectively labeled with the radiotracer [18F]FDG using optimized incubation parameters. The biodistribution and homing of the labeled NK cells into the tumor tissue could be demonstrated with digital autoradiography. As shown by our data, we could prove the differential tumor uptake of NK-92-scFv(FRP5)-zeta cells versus parental NK cells within a 2-h time frame, although tumor
References (43)
- et al.
A Phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma
Lung Cancer
(2001) - et al.
Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction
Blood
(2002) - et al.
A method for labeling cells for positron emission tomography (PET) studies
J Immunol Methods
(1994) - et al.
Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo
Breast Cancer Res Treat
(2007) - et al.
Antibody-dependent cell cytotoxicity to breast cancer targets despite inhibitory KIR signaling
Anticancer Res
(2006) - et al.
Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92
J Hematother
(1999) - et al.
Regulation of the natural killer cell receptor repertoire
Annu Rev Immunol
(2001) Immune cells in the tumor microenvironment—mechanisms responsible for functional and signaling defects
Gene Therapy of Cancer
(1998)- et al.
A Phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia
Leuk Lymphoma
(1998) - et al.
Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92
J Hematother Stem Cell Res
(2001)
Antileukemia activity of a natural killer cell line against human leukemias
Clin Cancer Res
A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood
Biol Blood Marrow Transplant
Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors
Adv Cancer Res
The ErbB signaling network: receptor heterodimerization in development and cancer
EMBO J
In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging
Eur Radiol
Biodistribution of radiolabeled lymphocytes
Radiology
Imaging of activated natural killer cells in mice by positron emission tomography: preferential uptake in tumors
Cancer Res
Ex vivo cell labeling with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography
Proc Natl Acad Sci U S A
Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time
Diabetes
Kinetics of in vivo homing and recruitment into cycle of hematopoietic cells are organ-specific but CD44-independent
Bone Marrow Transplant
Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy
Eur J Nucl Med Mol Imaging
Cited by (64)
Molecular imaging of innate immunity and immunotherapy
2023, Advanced Drug Delivery ReviewsPresent status and future trends in molecular imaging of lymphocytes
2023, Seminars in Nuclear MedicineImaging the immune cell in immunotherapy
2022, NK Cells in Cancer Immunotherapy: Successes and ChallengesThe emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy
2021, Molecular Therapy OncolyticsCitation Excerpt :In vivo, cell therapy with ErbB2-CAR-NK-92 suppressed the tumor growth of human-ErbB2+ NIH 3T3 fibroblasts in CD-1 nude mice.76 ErbB2-CAR-NK-92 cells were also demonstrated to migrate and accumulate in ErbB2+ tumors, further illustrating the specificity of the modified cells.79–81 Second-generation ErbB2-CAR-NK-92 cells that included the costimulatory CD28 domain in addition to CD3ζ displayed increased cytotoxicity compared to the first-generation CAR72 and exhibited potent antitumor activity in glioblastoma82 and breast cancer models.83
Nuclear imaging for immune cell tracking in vivo – Comparison of various cell labeling methods and their application
2021, Coordination Chemistry Reviews